Warhound Launches With $200 Million To Create Engineered Military Canines

Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril have officially pulled the curtain back on a new venture called Warhound. The company emerged from stealth mode this Thursday with a significant $200 million funding round. This capital comes from a group of investors that includes Sequoia, 8VC, Corner Ventures, and In-Q-Tel. In-Q-Tel is a venture firm supported by the CIA and other U.S. intelligence agencies. This investment values the new enterprise at $1.2 billion.

The core mission of Warhound is to address a growing gap in the U.S. military’s working dog supply. Currently, more than 80% of these dogs originate in Europe, and fewer than half are deemed fit for service. Lamm and Luckey plan to change this dynamic by creating dogs specifically engineered for dangerous tasks like bomb detection and complex searches. These roles are often too risky for humans or too difficult for current machine technology.

Lamm explained that he met Luckey at a conference a year ago. Their conversation led Lamm to research the breeding habits of working dogs. He discovered that many animals fail training due to inherited issues such as poor eyesight, hip dysplasia, or muscle atrophy. The team has now begun collecting cell lines from high-performing breeds like the Belgian Malinois and German Shepherd. They are storing these in a biobank to edit the genes for better health, longevity, and enhanced sensory capabilities.

Anduril will provide the technological layer for these animals. The company plans to supply software and hardware, including protective vests and goggles. These tools are designed to give handlers better situational awareness. Lamm described the concept as adding technology on top of the dog rather than inside it. This approach aims to make the animals safer and healthier while also protecting the human handlers working alongside them. Luckey serves as a partner in the venture but does not hold any equity. Colossal holds equity and licenses its technology to the project.

The timeline for this project is aggressive but clear. The first batch of dogs is currently being cloned and incubated. Births are expected in early 2027, with service potentially beginning within two years. Viagen, another company owned by Colossal, will handle the cloning process. This partnership leverages technology that Colossal already uses for its de-extinction efforts and endangered species programs.

Warhound has not yet determined the pricing for these engineered dogs. However, the company expects to sell them to first responders, the Department of Defense, and police forces. Regarding safety and ethics, the company is working under the guidance of the American Humane Society. The Society is helping to certify the training program. The group stated that they applaud Warhound and Colossal for inviting them to the table to ensure the animals are treated humanely.

Open questions remain about how these dogs will be managed in the field. Lamm noted that each animal will be trained like any standard military working dog and managed by the buyer. The company has briefed various government groups on the business model. As the first clones prepare to enter the world, the industry will be watching closely to see if this hybrid of biology and technology can meet its promises.